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Background/Purpose: This study aims to evaluate the clinical characteristics and visual outcome of
macular hemorrhage in pathological myopia with or without choroidal neovascularization.
Methods: We conducted a retrospective study of 55 patients with macular coin hemorrhage who were
followed for at least 3 months from January 1997 to December 2013 at Shin Kong Wu Ho-Su Memorial
Hospital (Taipei, Taiwan). All patients were evaluated using ﬂuorescein angiography and optical coher-
ence tomography for the detection of choroidal neovascularization (CNV). We also recorded clinical
characteristics such as age, sex, refractory error, and myopic fundus, to determine the relationship be-
tween CNV and non-CNV associated macular hemorrhage.
Results: A total of 55 patients (30 females, 54.55%) were reviewed. The mean age was 39.7 years old. The
CNV group was found to be signiﬁcantly older than the non-CNV group (p < 0.05), and there was no
signiﬁcant difference between sex, visual acuity myopic severity, and the prevalence of fundus ﬁndings
between CNV and non-CNV groups. Twenty one patients (38.18%) were found to have CNV and were all
treated with intravitreal antivascular endothelial growth factor (VEGF). The other 34 patients without
CNV were not treated. In both groups, the visual acuity signiﬁcantly improved (anti-VEGF treated, CNV
associated group, 0.7 to 0.39, p ¼ 0.002, and untreated, non-CNV associated group, 0.56 to 0.34,
p ¼ 0.0018, respectively).
Conclusion: Age signiﬁcantly correlated to the CNV formation in high myopia with macular hemorrhage.
Favorable visual outcomes were found in pathological myopic macular hemorrhage either in the anti-
VEGF treated, CNV associated group or in the untreated, non-CNV associated group.
Copyright © 2016, The Ophthalmologic Society of Taiwan. Published by Elsevier Taiwan LLC. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Pathologic myopia (PM) is a major vision-threatening morbidity
throughout the world and has been found to be increasing in fre-
quency inmany countries, especially in Asia. It is estimated to affect
1.4e2.5% of the general population in Western countries,1e3 and
6.8e26% in East Asia,4e7 including Korea, China, and Taiwan. A
higher prevalence was found in younger generations, or people
living in urban areas in these countries.4e7 Consequently, compli-
cations of pathological myopia may pose great socioeconomice no conﬂicts of interest.
ology, Shin Kong Wu Ho-Su
strict, Taipei 11106, Taiwan.
, ckcheng.md@gmail.com
iety of Taiwan. Published by Elseviimpacts in East Asian countries because it can lead to vision loss in
people of working age.5 One of the major complications of PM is
macular hemorrhage, which often presents with sudden impair-
ment of visual acuity (VA) in the affected patients. The pathogen-
esis of macular hemorrhage in PM may be related to either simple
rupture of Bruch's membrane, or a bleeding from concurrent
choroidal neovascularization (CNV). The presence of CNV is
particularly detrimental to long-term visual function when
involved in the foveal area, because it would usually lead to scar
formation,8 as in age-related macular degeneration (AMD) or other
choroidal pathologies. Recently, inhibitors of vascular endothelial
growth factor (VEGF) have been used for the treatment of CNV in
PM with good results.8 As a result, prompt detection of the
concurrence of CNV in PM patients presenting with macular
hemorrhage is of great importance in regard to treatment choices
and prognosis. The purpose of this study is to identify the clinicaler Taiwan LLC. This is an open access article under the CC BY-NC-ND license (http://
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patients with or without choroidal neovascularization.2. Methods
We conducted a retrospective chart review of 55 patients with
PM and subretinal coin hemorrhage at Shin Kong Wu Ho-Su Me-
morial Hospital, Taipei, Taiwan, between 1997 and 2013. The study
passed the institutional review board of our hospital and was
conducted according to the principles of the Declaration of Helsinki
for human participants. The inclusion criteria comprised:
1. Patients with at least one of the following conditions: (a)
refractive error < 6 D when the macular hemorrhage was
found; (b) previous documented refractive data < 6 D before
receiving refractive surgery or cataract surgery; (c) axial
length > 26.5 mm of the involved eye.
2. The fundus of patients in which characteristic ﬁndings sug-
gested pathological myopia, such as tessellated fundus,
geographic atrophy, posterior staphyloma, lacquer cracks and
Fuchs' spot formation.
The subretinal hemorrhage was deﬁned as one or more reddish
spots found in the subfoveal and juxtafoveal (<200 mm from the
fovea center) area in the ophthalmoscopic examination and
recorded in the color fundus photographs. Our study excluded
patients suspected to have AMD, any retinal vasculopathies
(including diabetic retinopathy, retinal vein occlusions, retinal
vasculitis, etc.), advanced glaucoma, or intraocular pressure in the
study eye >22 mmHg despite adequate treatment, and acute ocular
or periocular infection. Recurrence of macular hemorrhage was
deﬁned as the reappearance of any macular hemorrhage after a
complete absorption of the previous macular hemorrhage in any
follow-up visit.
Differentiation of macular hemorrhage associated with or
without myopic CNV was made by a combination of ﬂuorescein
angiography (FA) (Heidelberg Retina Angiograph2; HeidelbergFigure 1. A 46-year-old woman with macular hemorrhage due to myopic choroidal neovasc
time-domain optical coherence tomography.engineering, Heidelberg, Germany) and optical coherence tomog-
raphy (OCT) (Stratus, Zeiss, Model 3000; Carl Zeiss Meditec, Inc.,
Dublin, CA, USA) modiﬁed from previous published literature.9,10
The diagnostic criteria for CNV in FA included a patch of lacy or
irregular hyperﬂuorescence in the early arteriovenous phase,
leakage of dye from the lesion in the late arteriovenous phase, and
staining of the lesion with ﬂuorescein in the late phase. In most
cases, a hyperpigmented ring was found around the hyper-
ﬂuorescent CNV. The OCT criteria for CNV included an elevated
submacular hyperreﬂective lesion with evidence of exudative
characteristics, including subretinal ﬂuid, macular thickening, or
retinal cysts (Figure 1). Macular hemorrhage without myopic CNV
was deﬁned as ﬂat or elevated submacular hyperreﬂective lesions
without evidence of exudative characteristics on OCT, and hypo-
ﬂuorescence of lesionwithout accompanying dye staining, leakage,
and hyperﬂuorescence on FA (Figure 2).
If myopic CNV was detected, further intravitreal injection of
anti-VEGF was arranged. Otherwise, the non-CNV patients were
only observed.
In this study, we aimed to identify the visual outcomes and
accompanying ﬁndings in patients with and without myopic CNV.
We evaluated the patients' best corrected visual acuity (BCVA)
during every visit using a Snellen chart in a standard condition.
BCVA was then converted to logarithm of minimal angle of reso-
lution (logMAR) for statistical analysis. The ManneWhitney U test
was used to assess the numerical clinical characteristics, such as age
and refraction, between CNV and non-CNV groups. A paired t-test
was used to compare changes in VA from baseline to the 3-month
follow up in all patients within both myopic CNV and non-CNV
groups. The categorical clinical characteristics, including sex, lac-
quer cracks, Fuchs' spot, and geographic atrophy were compared
using a Chi-squared test. Values of p < 0.05 were considered sta-
tistically signiﬁcant.
3. Results
A total of 55 eyes in 55 patients (30 females, 54.55%) who had
PM with macular hemorrhage were included in this study. Theularization (arrows in A and B). (A) Color fundus; (B) ﬂuorescein angiography; and (C)
Figure 2. A 39-year-old woman with macular hemorrhage without myopic choroidal neovascularization (arrows in A and B). (A) Color fundus; (B) ﬂuorescein angiography; and (C)
time-domain optical coherence tomography.
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refractory error was 14.31 ± 4.06 D. The prevalence of lacquer
crack, Fuchs' spot, and geographic atrophy were found to be 20.0%,
14.5%, and 7.3%, respectively in our patients. Twenty one patients
(38.18%) were found to have CNV and were treatedwith intravitreal
anti-VEGF (bevacizumab: 19 patients; ranibizumab: 2 patients).
The CNV group had a mean of 1.5 ± 0.7 (range 1e3) injections
during a mean period of 6.1 ± 4.8 (range 1e20) months of their
clinical follow up. The other 34 patients without CNV were not
treated [mean follow-up time of 1.7 ± 1.3 (range 1e5) months].
3.1. Clinical characteristics
The CNV groupwas found to be signiﬁcantly older than the non-
CNV group (44.0 ± 22.9 years vs. 37.0 ± 19.8 years, respectively,
p¼ 0.024). There was also a more frequent occurrence of the Fuchs'
spot in the CNV group (p ¼ 0.021). Otherwise there was no signif-
icant difference in sex, refractory error, presenting VA, and other
fundus ﬁndings such as lacquer crack and geographic atrophy be-
tween the CNV and non-CNV groups (Table 1).
3.2. Visual outcome
Baseline and 3-month VA outcomes are shown in Figure 3.
Thirteen (three in the CNV group, 10 in the non-CNV group) of theTable 1
The clinical features, except age and Fuchs' spot, had no relationship in CNV and
non-CNV groups.
CNV Non-CNV P
Sex (male) 11 (52.4%) 14 (41.2%) 0.417a
Age (y) 44 ± 22.9 37 ± 19.8 0.024b
Refraction (diopter) 13.6 ± 4.1 14.8 ± 3.9 0.114b
Lacquer crack 4 (19.0%) 7 (20.6%) 0.692a
Fuchs' spot 6 (28.6%) 2 (5.9%) 0.021a
Geographic atrophy 2 (9.5%) 2 (5.8%) 0.617a
CNV ¼ choroidal neovascularization.
a Chi-square test.
b ManneWhitney U test.patients who lost follow up at 3 months were excluded from the
statistical analysis of the visual outcomes. The range of BCVAwhen
patients enrolled in the CNV group was from 1.30 to 0.22, mean
BCVA was 0.7 ± 0.35; and in the non-CNV group was from 2.00 to
0.00, mean BCVA was 0.56 ± 0.56. Patients with or without CNV
both showed signiﬁcant improvement in BCVA. The BCVA in the
anti-VEGF treated, CNV associated group improved from 0.7 to 0.39
(Snellen equivalent 6/30 to 6/15), p ¼ 0.002. The BCVA in the un-
treated, non-CNV associated group improved from 0.56 to 0.34
(Snellen equivalent 6/22 to 6/13), p ¼ 0.0018. There was no sig-
niﬁcant difference in improvement of BCVA between the non-CNV
group and the CNV group (p ¼ 0.168).4. Discussion
High myopia is often regarded as the most important risk factor
for the development of CNV in young patients (50 years of age),
regardless of ethnic group.11 While the presence of CNV is the most
important pathology for macular hemorrhage in aged patients withFigure 3. The visual outcome of patients with and without CNV. The BCVA of the CNV
associated group improved from 0.7 to 0.39, p ¼ 0.002. The non-CNV associated group
improved from 0.56 to 0.34, p ¼ 0.0018. BCVA ¼ best corrected visual acuity;
CNV ¼ choroidal neovascularization; VA ¼ visual acuity.
Table 2
Number of patients with recurrent macula coin hemorrhage.
Recurrent with CNV Recurrent without CNV
CNV group 5 2
Non-CNV group 3 6
CNV ¼ choroidal neovascularization.
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found that a concurrent presence of CNV was found in only 21
(38.18%) of 55 PM patients who presented with fresh symptomatic
macular hemorrhage. We also revealed that patients with macular
hemorrhage and concurrent CNV were signiﬁcantly older
(44.0 ± 22.9 years vs. 37.0 ± 19.8 years respectively, p ¼ 0.024) and
had a greater prevalence of Fuchs' spot (p ¼ 0.021) than those
without concurrent CNV. Other clinical features including sex,
refractive error, lacquer cracks, and geographic atrophy were not
statistically different between the two groups.
The pathogenesis of macular hemorrhage is not fully under-
stood in patients with PM but without CNV.12 It is postulated that
the elongation of the eyeball in PM may induce the rupture of
Bruch's membrane and choriocapillaris, resulting in a spreading-
out of the hemorrhage into the subretinal space or even the
retinal tissue. However, macular hemorrhage associated with CNV
may more likely be a result of bleeding of fragile new vessels in the
CNV tissue. The pathogenesis of the development of CNV in AMD
has been postulated to be a consequence of focal secretion of
angiogenic factors, such as VEGF from the ischemic tissues in the
older macular area, which result from the accumulation of water
insulating metabolic waste known as drusen. However, the path-
ogenesis of the development of CNV in PM may be different since
there is usually not much drusenmaterial in the macula of PM eyes.
Nevertheless, recent evidence suggests that CNV in both PM and
AMD could be treated successfully with anti-VEGF agents. It is
therefore possible that a common pathway in the pathogenesis
involving VEGF, and thus ischemic conditions may occur in both PM
and AMD.
One possible mechanism of ischemic change in the macula of
PMmay be related to a decrease in choroidal thickness.13e15 Flores-
Moreno et al14 reported a decrease in choroidal thickness by
25.9 ± 2.1 mm for each additional millimeter in high myopia. Ikuno
et al15 found that thinner choroid is a risk factor for the develop-
ment of CNV in PM. There is also evidence suggesting that older
patients with PM may suffer from more ischemic conditions than
younger patients.16 Many studies have reported that choroidal
thickness decreases with increased age in the normal population,
with a 14e15.6-mm decrease each decade.17e19 Ho et al16 further
demonstrated that in myopia patients, choroidal thickness de-
creases not only with the severity of myopia, but also signiﬁcantly
with age. This may be a mechanism that supports our ﬁnding that
patients with concurrent CNV are signiﬁcantly older than patients
without concurrent CNV. In 1990, Hayasaka et al20 also reported
that the subretinal hemorrhages without CNV were more frequent
in younger patients (mean 36.8 years old), while CNV was more
common in older patients (mean 61 years old).
The appearance of the Fuchs' spot in the fundus also correlated
with concurrent CNV in PM patients with macular hemorrhage. A
Fuchs' spot represents an old scar of previous CNV.21 This result
suggests that eyes with previous CNV were more prone to have
recurrent CNV in PM patients. Interestingly, in our study we found
that the occurrence of macular hemorrhage in the CNV group was
most likely due to a new CNV formation instead of recurrence from
previous Fuchs' spots. During FA examination, we found new CNV
in ﬁve out of seven eyes with macular hemorrhage in the CNV
group (Table 2).
However, in this study we found that there was no statistically
signiﬁcant correlation between concurrent CNV and other fundus
ﬁndings such as lacquer cracks or patchy chorioretinal atrophy.
Lacquer cracks are caused by stretching and rupture of the Bruch's
membrane-pigment epithelium-choriocapillaris complex.12,22,23
The formation of lacquer cracks may be associated with sub-
retinal hemorrhage but are usually not found to be associated with
concurrent CNV.12,22,23 The prevalence of lacquer cracks in PM wasvery variable in previous studies. Some studies reported a preva-
lence of 0.6e4.2%,24,25 while another study reported that lacquer
cracks were noted in 82% of 149 eyes with CNV and in 96% of 58
eyes with isolated subretinal hemorrhages.26 In this study, we did
not ﬁnd such a high occurrence in our PM cases. We only found
lacquer cracks in 19% of the isolated macular hemorrhage group
and 20.6% of the concurrent CNV group during the fundus exami-
nation. Patchy chorioretinal atrophy is another characteristic
ﬁnding in myopic maculopathy, and was reported to be present in
11.4% of fundus ﬁndings in PM eyes.24 In our patients, it presented
in only four cases (7.3%). Both lacquer cracks and patchy chorior-
etinal atrophy did not signiﬁcantly differ in prevalence between the
CNV and non-CNV groups in our study (Table 1). Also the refractive
error was not found to be associated with the concurrent CNV in
our study, which was similar to the conclusion of an earlier study
conducted by Hayasaka et al.20
In our study, we found that BCVA in PM eyes with solitary
macular hemorrhage improved spontaneously from 0.56 to
0.34 logMAR (SE 6/22 to 6/13) in 3 months without treatment.
Several studies have revealed similar results. The VA in patients
with subretinal hemorrhage but no neovascular membrane detec-
ted had a fair visual improvement rate.27 Hayasaka et al20 reported
that the macular hemorrhages in PM reabsorbed almost completely
within 3 months. Li et al28 reported that the VAs of macular hem-
orrhage in pathological myopia without choroidal neovasculopathy
improved spontaneously in 81.6% of eyes during the following
3e21 months. However, PM with subfoveal CNV usually would not
get better without treatment.29 The Verteporﬁn in Photodynamic
Therapy (VIP) Study reports that untreated eyes with PM and CNV
deteriorate a median of 1 line in 3 months and 1.8 lines in
12 months.30 Recently, anti-VEGF has been shown to be effective in
improving visual outcome in PM with CNV, and has been shown to
be more effective than photodynamic therapy.31e34 Several studies
have reported that anti-VEGF is effective not only for short-term but
also for long-term visual outcomes.35e37 However, most studies did
not focus on PM patients with current CNV and macular hemor-
rhage. Our study speciﬁcally revealed that in PM eyes with CNV and
concurrent macular hemorrhage, anti-VEGF treatment could
signiﬁcantly improve BCVA from a mean of 0.7 to 0.39 logMAR
(SE 6/30 to 6/15) in 3 months, which is similar to the spontaneous
improvement of solitary macular hemorrhage without treatment.
In conclusion, our study revealed that approximately 38% of
Taiwanese patients with myopic macular hemorrhage were asso-
ciated with concurrent CNV. These patients tend to be older and
have more occurrences of Fuchs' spots. We also revealed that in
patients with concurrent CNV and macular hemorrhage, anti-VEGF
is very effective in improving their visual outcomes. However, in
eyes with solitary macular hemorrhage, observations could lead to
similar favorable visual outcomes. However, there were several
limitations in our study such as the retrospective design, limited
case numbers and very short-term results. Up to 23.6% (13 in 55) of
patients failed to visit for longer than 3 months, which further
compromised the accuracy of our outcomemeasures. Nevertheless,
our results suggest that in PM patients with newly occurred mac-
ular hemorrhage, a detailed investigation for the concurrence of
CNV using FA and OCT is necessary to determine a more appro-
priate strategy of treatment.
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